Efficiency of verapamil was studied in secondary prophylaxis of phasic affective disorders, 50 patients with affective and schizoaffective psychoses were treated during 2 years. Daily dose of verapamil was 80-320 mg (average dose-240 mg). Three groups were formed. Group 1 (10 patients) included patients which didn't receive any prophylactic therapy during previous 2 years. In group 2 (25 patients) and 3 (15 patients) verapamil was administrated after 2 years of prophylactic therapy with either lithium carbonate or carbamazepine, respectively. Clear prophylactic activity of verapamil was observed. There was preference of its reducing effect on the depressive phases. The data obtained and good tolerance of verapamil evidence for effectiveness of prolonged administration of this preparation as a drug with antirelapsed properties.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Deciding to Be Left Alone After Being Left Out: Behavioral Responses to Social Exclusion in Schizophrenia.
Schizophr Bull
January 2025
Department of Psychology, University of California, Berkeley, CA 94720, United States.
Background And Hypotheses: People with schizophrenia are at risk for social exclusion, yet we know little about their responses. We hypothesized (1) people with schizophrenia would be more likely to withdraw following social exclusion compared to controls; (2) withdrawal intentions would be greater following exclusion compared to disappointment; (3) withdrawal behavior would be predicted by rejection sensitivity, alternative sources of acceptance, chronicity of exclusion, and perceived fairness; and (4) withdrawal following exclusion would be associated with more negative symptoms and poorer functioning.
Study Design: People with (n = 43) and without (n = 43) schizophrenia or schizoaffective disorder played Cyberball - Behavioral Response, a novel version of the exclusion task.
Neurobiological correlates of comorbidity in disorders across the affective disorders-psychosis spectrum.
J Psychiatr Res
December 2024
Institute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn, Bonn, Germany; Institute of Neuroscience and Medicine (INM-1), Research Centre Jülich, Jülich, Germany; Centre for Human Genetics, Philipps-University Marburg, Marburg, Germany. Electronic address:
Disorders across the affective disorders-psychosis spectrum such as major depressive disorder (MDD), bipolar disorder (BD), schizoaffective disorder (SCA), and schizophrenia (SCZ), have overlapping symptomatology and high comorbidity rates with other mental disorders. So far, however, it is largely unclear why some of the patients develop comorbidities. In particular, the specific genetic architecture of comorbidity and its relationship with brain structure remain poorly understood.
View Article and Find Full Text PDFThe Modern Concept of Schizoaffective Disorder: A Narrative Review.
Consort Psychiatr
September 2024
Background: Schizoaffective disorder (SAD) is one of the most complex and controversial diagnoses in clinical psychiatry. Despite the significant changes that have occurred in the conceptualization of SAD in modern classifications and the publications of recent years, many unresolved issues remain regarding the disease, from the point of view of clinical psychiatry and basic neuroscience.
Aim: The purpose of this paper is to summarize published data on the concept of SAD, its clinical characteristics, cognitive profile, potential biomarkers, as well as the place of the disease in the following modern international classifications: the International Classification of Diseases (ICD) 9, 10 and 11 revisions, and the Diagnostic and Statistical Manual of Mental Disorders, 5 edition (DSM-5).
Australian community and inpatient general public sector mental health services between 2017-18 and 2021-22: Relative stasis in bed capacity, increasing outpatient demand, and stunted expenditure.
Australas Psychiatry
November 2024
Consortium of Australian-Academic Psychiatrists for Independent Policy and Research Analysis (CAPIPRA), Canberra, ACT, Australia; Department of Psychiatry, The Canberra Hospital, Garran, ACT, Australia; Academic Unit of Psychiatry and Addiction Medicine, School of Medicine and Psychology, Canberra Hospital, The Australian National University, Canberra, ACT, Australia.
Objective: To descriptively analyse Australian public sector General Mental Health Services (GMHS) expenditure, ambulatory, and inpatient services, including key performance indicators (KPIs) in comparison with other subspeciality mental health services (MHS).
Method: We descriptively analysed data published by the Australian Institute of Health and Welfare (AIHW), including inpatient, ambulatory services, expenditure, and KPIs.
Results: From 2017-18 to 2021-22, per capita expenditure for Australian GMHS (18-64) rose by an average annual inflation-adjusted change of 2%.
Managing COVID-19 patients with mental illness in a specialized neuropsychiatric setting: An experience from a tertiary care hospital in India.
Australas Psychiatry
October 2024
Department of Psychiatry, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, India.
Article Synopsis
- The study aimed to understand how COVID-19 affected patients with mental illnesses in a specialized neuropsychiatric setting by analyzing a group of 100 patients from June 2020 to June 2022.
- The majority of patients had schizophrenia, bipolar disorder, or schizoaffective disorder, with most requiring antipsychotics; 56% experienced mild symptoms while 38% were asymptomatic.
- The research highlighted the need for specialized psychiatric care for COVID-19 patients with mental health issues, due to the complexity of their symptoms and medical management challenges.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!